GlassScriptPhysician profile
Jenna E Fluegge
NPI 1417390212
$1,702.45
in general payments reported to CMS, 2019-2025
19 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.75 · 2020: $36.35 · 2021: $35.43 · 2022: $129 · 2023: $408 · 2024: $570 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.71 | 2023-2025 | |
| Novo Nordisk INC | $330.25 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $204.59 | 2019-2025 | |
| Exact Sciences Corporation | $132.48 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $112.83 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Glaxosmithkline, LLC. | $83.69 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $61.18 | 2022-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $45.50 | 2019 | |
| Astellas Pharma US INC | $45.45 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $44.11 | 2023-2024 | Quviviq |
| Amgen INC. | $43.21 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.22 | 2023-2024 | Jardiance, Synjardy |
| Nevro Corp. | $24.35 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.82 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $14.60 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $13.47 | 2022 | |
| Lupin INC. | $13.16 | 2019 | |
| Phadia US INC. | $12.77 | 2022 | |
| Sanofi Pasteur INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Fluegge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.